Trial Profile

An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
Indications Non-small cell lung cancer
Focus Biomarker; Pharmacogenomic; Therapeutic Use
Acronyms BELIEF

Most Recent Events

05 Dec 2019 Results published in the Journal of Thoracic Oncology.
02 Nov 2018 Status changed from active, no longer recruiting to completed.
23 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com